Journal of Clinical Oncology
Articles in this Issue
Circulating tumor DNA assessment in patients with early-stage classical Hodgkin lymphoma treated with combination of brentuximab vedotin and nivolumab.
7040 Background: Recent data suggest circulating tumor DNA (ctDNA) can be detected in patients with classical Hodgkin lymphoma (cHL), with molecular respo...
Impact of palliative care on mortality, length of stay, and hospital charges in common cancers.
12087 Background: Palliative care is a vital component of advanced cancer management, offering symptom relief, improved quality of life, and comprehensive...
Molecular testing and targeted therapy use in lung cancer across state Medicaid programs.
11036 Background: Comprehensive molecular testing is the standard of care for patients with metastatic non-small cell lung cancer (NSCLC) and is essential...
5-FU + Naliri, gemcitabine plus nab-paclitaxel or both regimens given sequentially for first line treatment of metastatic pancreatic ductal adenocarcinoma: A randomized phase II comparative study (FUNGEMAX-PRODIGE 61).
4184 Background: New chemotherapeutic approaches are still needed to improve survival and quality of life in metastatic pancreatic ductal adenocarcinoma (...
Real world outcomes of darolutamide efficacy and safety in treating non-metastatic and metastatic hormone-sensitive prostate cancer.
e17108 Background: Darolutamide is a next-generation androgen receptor inhibitor, used in the treatment of prostate cancer. There is currently limited rea...
EATON: A phase I trial of nazartinib (EGF816) and trametinib in EGFR-mutant (EGFRmut) non-small cell lung cancer (NSCLC).
8619 Background: EGFR inhibitors (EGFRi) are highly effective in EGFRmut NSCLC, but resistance inevitably emerges. Among the mechanisms of acquired resist...
How cancer impacts adolescents’ and young adults’ (AYAs) scholastic experiences: Insight on supportive survivorship care needs from AYAs, parents, and clinicians.
11053 Background: Cancer disrupts AYAs’ educational and vocational trajectories given treatment demands and acute or late effects of treatment on cognitiv...
An open-label, phase I trial of the SIRPα monoclonal antibody, BI 770371, alone and in combination with the PD-1 inhibitor ezabenlimab in patients with advanced solid tumors.
2515 Background: The signal regulatory protein alpha (SIRPα)/CD47 axis is a critical regulator of myeloid cell activation and serves as a myeloid-specific...
Improving genetic counseling uptake for breast, pancreatic, and prostate cancers at a safety net hospital.
11137 Background: Despite guideline recommendations, genetic counseling (GC) for BRCA associated cancers among underserved populations remain low. We cond...
Evaluating the association between dietary zinc intake and cancer risk: Insights from NHANES 2021–2023 with stratified and multivariate analyses.
e22589 Background: Various studies have examined the relationship between dietary zinc (Zn) intake and cancer risk. While some have shown no substantial l...
Neoadjuvant treatment with disitamab vedotin monotherapy in patients with HER2-overexpressing muscle invasive bladder cancer (MIBC): An open-label, single-arm, phase II study.
e16584 Background: Radical cystectomy with pelvic lymph node dissection and urinary diversion (RC+PLND+/-UD) is considered the standard of care for patien...
Efficacy of adjuvant anti-PD-1 antibodies and interferon in patients with nail apparatus melanoma: A retrospective, multicenter study (ADJ-NAIL study).
9572 Background: The clinical efficacy of anti-PD-1 antibodies (PD-1) for nail apparatus melanoma (NAM) is less effective than that for advanced cutaneous...
Ultrasensitive ctDNA profiling to identify long-term survivors in phase I immunotherapy trials.
2560 Background: Patients (pts) included in early clinical trials (ECT) typically show a median overall survival of 8-10 months (PMID: 18042834 and 219750...
Enhancing lung cancer surgical quality: Insights from a national quality improvement collaborative.
11140 Background: Sampling of at least 3 mediastinal and at least 1 hilar lymph node stations during lung cancer resection was adopted by the American Col...
Preliminary result of a phase Ib study: Efficacy and safety of FG-M108 plus gemcitabine and nab-paclitaxel in patients with Claudin18.2-positive, locally advanced, unresectable, or metastatic pancreatic cancer.
4188 Background: FG-M108, an ADCC-enhanced anti-CLDN18.2 monoclonal antibody, showed significant efficacy in first-line (1L) treatment of gastric cancer....
A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors.
2558 Background: Clinical validation studies have shown that early dynamic changes in circulating tumor DNA (ctDNA) tumor fraction (TF) can predict clinic...
Dara VCD: Outcomes of frontline therapy for light-chain amyloidosis.
e19574 Background: Daratumumab, bortezomib, cyclophosphamide, and dexamethasone (Dara-VCD) is an FDA-approved frontline treatment for AL amyloidosis with...
A pooled analysis of clinical outcomes with anti-PD1-based neoadjuvant immunotherapy (NeoIT) in cutaneous squamous cell carcinoma (cSCC).
9578 Background: Anti-PD1 immunotherapy has shown improved clinical outcomes in patients (pts) with advanced cSCC, and recently, in the neoadjuvant settin...
Germline genetic testing for hereditary cancer syndromes among newly diagnosed patients with solid tumors: A report of 10,000 patients from the Jordanian Exploratory Cancer Genetics study.
10592 Background: Hereditary factors play a key role in the risk of developing several cancers. Identification of germline cancer predisposing genes can h...
Shifting landscape of resistance to next-generation ALK inhibitors with evolving treatment paradigm in ALK+ lung cancer.
8607 Background: Next-generation (gen) ALK tyrosine kinase inhibitors (TKIs) are standard first-line (1L) therapy for patients (pts) with ALK...
HERA-TEST: A novel precision oncology tool using breast milk for early detection of postpartum breast cancer.
TPS10627 Background: The incidence of breast cancer (BC) in women under the age of 45 has risen in recent decades, partly due to delayed childbearing. Mor...
Genetic epidemiology of colorectal cancer in Morocco: A systematic review and meta-analysis.
e15695 Background: Colorectal cancer is a major cause of morbidity and mortality worldwide, ranking among the most common types of cancer. In North Africa...
Decoding NAMPT and TIGAR: A molecular blueprint for reprogramming tumor metabolism and immunity.
e14537 Background: NAMPT and TIGAR, present in exosomes derived from pulsed dendritic cells (DEX), are key regulators of tumor metabolism and immune modul...
Impact of <i>TP53</i> mutation status on cancer-specific survival after first-line treatment in lymphoplasmacytic lymphoma.
e19573 Background: Lymphoplasmacytic lymphoma (LPL) is an indolent B-cell neoplasm encompassing Waldenström macroglobulinemia (WM) and non-IgM LPL. Testin...
Correlation of circulating tumor DNA (ctDNA) dynamics with clinical response in muscle-invasive bladder cancer (MIBC) patients (pts) undergoing trimodality therapy (TMT).
4602 Background: TMT is a curative treatment option for pts with MIBC. Plasma circulating tumor DNA (ctDNA) is associated with treatment response and clin...